← All trials
NCT02335879
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2008
- Primary completion
- Aug 1, 2009
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 534
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Wenzhou Medical UniversityCollaborator
- Shengjing HospitalCollaborator
- Shandong UniversityCollaborator
- Central South UniversityCollaborator
- Peking UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Jilin UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.